Over the years, May & Baker has continued to improve its year-end financial performance with a robust dividend policy. It is not surprising that it has become the toast of the investing public. That is why the public offer for subscription of our shares in the Nigeria Stock Exchange in 2006 was subscribed by 267 percent.

Our financial performance has not escaped the watchful eyes of the Nigeria Stock Exchange. In 1996, barely two years after getting listed, the company’s sterling performance was awarded with the prestigious Nigeria Stock Exchange Annual President’s Merit Award in the Healthcare/Chemicals and Paints category.

May & Baker again carted home the coveted prize in 1997, this time in the Healthcare/Pharmaceutical category. It has since then won the award two more times.

In 2004, May & Baker won the Gold Award of the Lagos State Ministry of Health in Occupational Health and Safety and in 2007 was awarded a prize of excellence in pharmaceutical manufacturing by the Federal Ministry of Health

In 2008, the company earned the much coveted NIS ISO 9001: 2000 certificate for its quality management system and its Food Division was also granted the Mandatory Conformity Assessment Certificate Programme (MANCAP) for its Mimee Noodles brands by the Standards Organization of Nigeria (SON).

The future outlook of the company and consequently for investors, is increasingly looking brighter as the company has emerged from a major transformation that has enabled it to diversity into foods and vaccines production. This transformation has also seen the company align its processes to the needs and expectations of its customers with greater efficiency and profitability.

In the first quarter of 2010, May & Baker will commission the first World Health Organisation (WHO) standard pharmaceutical plant in Nigeria, and one of the largest plants in Africa. The plant is scheduled to receive WHO Pre-Qualification Certificate within a year of its opening.